Reagents and instruments for immunology, cell biology and molecular biology.
 
> Cisplatin [15663-27-1]

Cisplatin [15663-27-1]

Print Print
Please log in

Cat# HY-17394-100mg

Size : 100mg

Brand : MedChemExpress

Request more information

Description

Cisplatin (CDDP) is an antineoplastic chemotherapy agent by cross-linking with DNA and causing DNA damage in cancer cells. Cisplatin activates ferroptosis and induces autophagy[1][2][3].

IC50 & Target

DNA Alkylator/Crosslinker[1]
In Vitro

Cisplatin (CDDP) causes apoptosis of HeLa cells in a dose-dependent manner, with a concentration of 30 μM Cisplatin resulting in death of greater than 90% of the cell population by 24 h of treatment. The kinetics of Cisplatin-induced apoptosis are examined using a 30 μM concentration. Cisplatin Activates the MEK/ERK Signaling Pathway, 20 and 30 μM Cisplatin, both of which results in significant apoptosis, leads to strong activation of ERK[1].
Cisplatin (50 μM) produces time-dependent apoptosis in renal proximal tubular cell (RPTCs), causing cell shrinkage, a 50-fold increase in caspase 3 activity, a 4-fold increase in phosphatidylserine externalization, and 5- and 15-fold increases in chromatin condensation and DNA hypoploidy, respectively[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cisplatin Related Antibodies
In Vivo

Cisplatin can be used to induce acute kidney injury models[7][8].

Induction of Acute Kidney Injury (AKI)[7][8]
Background
The pathogenesis of Cisplatin-induced acute kidney injury (AKI) is complex and Oxidative stress, mitochondrial dysfunction, inflammation, and apoptosis are all participating in the progression of Cisplatin-induced AKI.Oxidative stress is a predominant mechanism of injury in cisplatin-induced AKI.
Specific Modeling Methods
Mice: C57BL/6 • male • 6-week-old (period: 2 weeks)
Administration: 5 mg/kg • ip • once daily for 2 weeks
Note
(1) Suggest using male mice as female mice are more resistant to renal injury.
(2) Mice can be deprived of food and water for 18 h prior to induction, and food and water are returned after administration.
(3) Cisplatin can be dissolved in sterile saline solution to prepare injection working solution while protecting from light.
Modeling Indicators
Molecular changes: Increased indicators: Serum creatinine (SCr) levels, blood urea nitrogen (BUN) levels, neutrophil gelatinase-associated lipocalin (NGAL), 3-nitrotyrosine.
Correlated Product(s): 84-B10 (HY-44307)
Opposite Product(s): /

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
Molecular Weight

300.05

Formula

Cl2H6N2Pt
CAS No.
Appearance

Solid

Color

Light yellow to yellow

SMILES

Cl[Pt](Cl)([NH3])[NH3]
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility
In Vitro: 

DMF : 10 mg/mL (33.33 mM; ultrasonic and warming and heat to 60°C; DMSO can inactivate Cisplatin's activity)

H2O : 1 mg/mL (3.33 mM; ultrasonic and warming and heat to 60°C; DMSO can inactivate Cisplatin's activity)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 3.3328 mL 16.6639 mL 33.3278 mL
5 mM 0.6666 mL 3.3328 mL 6.6656 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  PBS

    Solubility: 0.91 mg/mL (3.03 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

  • Protocol 2

    Add each solvent one by one:  0.5% CMC-Na/saline water

    Solubility: 20 mg/mL (66.66 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
Purity & Documentation
References

You might also be interested by the following products:



Cat#
Description
Cond.
Price Bef. VAT
5301-SC
Stellate Cell Medium
 500ml